Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

导出 LinkOut

翻译打印收藏纠错

作者： Gabrielle M,Baker ^[1] ; Tiffany,Murphy ^[2] ; Thaddeus,Block ^[3] ; Dat,Nguyen ^[4] ; Frank J,Lynch ^[2]

作者单位： Department of Pathology, The University of Chicago, Chicago, IL, USA. ^[1] QualTek Molecular Laboratories, Newtown, PA, USA. ^[2] Corcept Therapeutics, Menlo Park, CA, USA ; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA. ^[3] Corcept Therapeutics, Menlo Park, CA, USA. ^[4]

关键词 glucocorticoid receptor immunohistochemistry mifepristone triple negative breast cancer

DOI 10.2147/CMAR.S91546

PMID 26673410

发布时间 2024-05-21

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览17

Cancer management and research

2015年7卷

361-8页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Cancer management and research

相似文献

Cancer management and research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer.

Cancer management and research

相似文献

Cancer management and research

相关期刊

检索历史清除